Rabbit Polyclonal CHRND Antibody

The CHRND antibody targets the delta subunit of the nicotinic acetylcholine receptor (nAChR), a critical ligand-gated ion channel involved in neuromuscular signal transmission. Encoded by the *CHRND* gene, this subunit assembles with α, β, and γ/ε subunits to form the mature receptor at the neuromuscular junction (NMJ). During development, the fetal γ subunit is replaced by the ε subunit postnatally, altering receptor properties. The CHRND antibody is primarily used in research to study nAChR structure-function relationships, synaptic plasticity, and neuromuscular disorders. Mutations in *CHRND* are linked to congenital myasthenic syndromes (CMS), characterized by muscle weakness due to impaired neuromuscular transmission. Autoantibodies against CHRND, though rare, have been implicated in autoimmune CMS, disrupting receptor clustering or ion channel function. In diagnostics, CHRND antibodies aid in identifying CMS subtypes or paraneoplastic neurological conditions. Experimental applications include immunohistochemistry to localize delta subunits in tissues, Western blotting for protein expression analysis, and functional studies using cell-based assays. Its role in NMJ pathology also makes it relevant for drug development targeting neuromuscular diseases. However, cross-reactivity with other nAChR subunits requires careful validation to ensure specificity in assays.